SYMPHONY™

science and pipeline

ARIA’S DRUG DISCOVERY ENGINE

Giving new life to data.
Human biology is complex, but today it has seen a big data revolution with technologies that can produce billions of data points to help us understand how diseases manifest and how we can treat them. AI is now at the forefront, but most AI-driven drug discovery platforms only analyze one or two types of data at a time, not fully considering the sophistication of human biology. This leads to siloed predictions based on a limited scope of disease understanding.

Symphony™ is different. 

Symphony™ is a highly customizable, proprietary, AI drug discovery platform purpose-built for biological discovery. It utilizes the widest biomedical data landscapes available in combination with a proprietary artificial intelligence platform.

It is the only drug discovery platform to integrate and simultaneously analyze multiple unrelated heterogeneous data types in one process in a fully traceable, rationalized approach.

  1. Significantly disease-modifying hits in preclinical animal models identified by Symphony; N=18 diseases, on average 10 molecules per disease
  2. Retrospective efficacy success rate of clinical trials of molecules identified by Symphony; N=30 diseases, 402 Ph2 CTs

A pipeline built with confidence.

Symphony™ not only breaks the data silos that challenge traditional drug discovery but gives Aria scientists the insights necessary to mitigate drug development risks and maximize the likelihood of choosing the best candidates for success at Phase 1 and Phase 2 milestones.

This allows us to choose candidates to advance that will be more likely to see clinical success. In fact, our combined likelihood of success in preclinical and Phase 2 milestones is over 50x higher than traditional research and development approaches.

A pipeline built with confidence.

Symphony™ not only breaks the data silos that challenge traditional drug discovery but gives Aria scientists the insights necessary to mitigate drug development risks and maximize the likelihood of choosing the best candidates for success at Phase 1 and Phase 2 milestones.

This allows us to choose candidates to advance that will be more likely to see clinical success. In fact, our combined likelihood of success in preclinical and Phase 2 milestones is over 50x higher than traditional research and development approaches.

  1. Significantly disease-modifying hits in preclinical animal models identified by Symphony; N=18 diseases, on average 10 molecules per disease
  2. Retrospective efficacy success rate of clinical trials of molecules identified by Symphony; N=18 diseases, 283 Ph2 CTs

Always improving prediction capabilities. 

Symphony™ continuously improves its prediction quality over time with an iterative approach to algorithm and data enhancements through its ability to rapidly intake new biomedical data in any form. Aria has released new versions of the Symphony™ platform more than 340 times to date, making it one of the most sophisticated drug discovery platforms in the industry.

For more information on how we make clinical predictions, click here

OUR PIPELINE

Aria has built a pipeline of novel candidates against intractable diseases that are advancing from preclinical into the clinical research process. Many have shown promising initial preclinical efficacy data in in vivo testing.

OUR PIPELINE

Aria has built a pipeline of novel candidates against intractable diseases that are advancing from preclinical into the clinical research process. Many have shown promising initial preclinical efficacy data in in vivo testing.